Share ownership Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 06:18:39 12/05/2026 pm IST			5-day change	1st Jan Change
1,680.75 ^DKK	+1.31%		-3.54%	-17.39%

12:05pm	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
11/05	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,23,50,721	5,97,29,702 ( 95.8 %)	26,19,405 ( 4.201 %)	95.8 %

Major shareholders: Genmab A/S

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 4.484 %	27,95,626	4.484 %	742 M kr
GENMAB A/S 4.437 %	27,66,533	4.437 %	734 M kr
Jan van de Winkel 1.057 %	6,58,932	1.057 %	175 M kr
AllianceBernstein Investments Taiwan Ltd. 0.7234 %	4,51,050	0.7234 %	120 M kr
Nykredit Bank A/S (Investment Management) 0.5369 %	3,34,792	0.5369 %	89 M kr
Robert W. Baird & Co., Inc. (Equity) 0.3512 %	2,18,967	0.3512 %	58 M kr
Sjunde AP-fonden 0.166 %	1,03,520	0.166 %	27 M kr
State Street Global Advisors Ltd. 0.1489 %	92,857	0.1489 %	25 M kr
Goldman Sachs Asset Management International 0.1283 %	80,004	0.1283 %	21 M kr
Carmignac UK Ltd. 0.1183 %	73,734	0.1183 %	20 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 2.312 %	1,44,18,462	2.312 %	382 M kr
AllianceBernstein LP 1.745 %	1,08,77,094	1.745 %	288 M kr
Paradigm BioCapital Advisors LP 1.129 %	70,39,834	1.129 %	187 M kr
Arrowstreet Capital LP 0.7984 %	49,78,058	0.7984 %	132 M kr
Aperio Group LLC 0.7019 %	43,76,179	0.7019 %	116 M kr
Renaissance Technologies LLC 0.5602 %	34,92,850	0.5602 %	93 M kr
Harding Loevner LP 0.5405 %	33,70,143	0.5405 %	89 M kr
Eaton Vance Management 0.2942 %	18,34,439	0.2942 %	49 M kr
First Trust Advisors LP 0.2142 %	13,35,273	0.2142 %	35 M kr
Goldman Sachs Asset Management LP 0.2138 %	13,33,303	0.2138 %	35 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	118.77%
Other	8.79%
Genmab A/S	4.44%
Individuals	1.12%
SEI Investments Co.	0.12%
Fifth Third Bancorp	0.08%
Regions Financial Corp.	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	90.16%
Bermuda	27.61%
Denmark	5.16%
United Kingdom	3.09%
Switzerland	2%
Individuals	1.12%
Canada	0.81%
Taiwan	0.72%
Norway	0.4%
Sweden	0.38%
Germany	0.3%
Ireland	0.3%
Netherlands	0.22%
Australia	0.18%
France	0.13%
Finland	0.1%
Italy	0.1%
Hong Kong	0.09%
Singapore	0.09%
Luxembourg	0.06%
Cayman Islands	0.06%
Japan	0.06%
Austria	0.05%
Belgium	0.05%
Spain	0.04%
Portugal	0.02%
China	0.02%
New Zealand	0.01%
South Africa	0.01%
Mexico	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

06/08 - Earnings release - Q2 2026

More about the company